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Repeated administration of morphine increases expression of
GluR1 (an AMPA glutamate receptor subunit) in the ventral
tegmental area (VTA) of the midbrain, an important neural sub-
strate for the rewarding actions of morphine. Microinjections of
a herpes simplex virus (HSV) vector that causes local overex-
pression of GluR1 (HSV-GluR1) into the VTA can enhance the
ability of morphine to establish conditioned place preferences,
suggesting that altered GluR1 expression in this region is di-
rectly associated with changes in the rewarding efficacy of
morphine. We now report that in rats given HSV-GluR1 directly
into the VTA, morphine is most rewarding when maximal trans-
gene expression is in the rostral VTA, whereas morphine is
aversive when maximal transgene expression is in the caudal
VTA. Dual-labeling immunohistochemistry shows that this dif-
ference cannot be explained by a different fraction of dopami-
nergic neurons infected in the rostral versus caudal VTA. No
such anatomical specificity is seen in rats given VTA microin-
jections of HSV-LacZ, a vector expressing a control protein
(b-galactosidase). These results suggest that distinct sub-
strates within the VTA itself differentially contribute to the re-
warding and aversive properties of opiates.
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The ventral tegmental area (VTA) of the midbrain contains the
cell bodies of the mesolimbic dopamine (DA) system, a major
neural substrate for many drugs of abuse (Koob and Nestler,
1997; Wise, 1998). The reward-related effects of systemic opiates
(Weeks and Collins, 1964; Rossi and Reid, 1976; Carlezon and
Wise, 1993) involve opioid receptors in the VTA: injections of
morphine directly into the VTA potentiate the rewarding impact
of hypothalamic brain stimulation (Broekkamp et al., 1976), es-
tablish conditioned place preferences (Bozarth, 1987), and rein-
force lever pressing (Bozarth and Wise, 1981). Additionally, VTA
injections of morphine reinstate extinguished responding in rats
trained to lever press for intravenous heroin (Stewart, 1984).
Opiates have their most potent reward-related effects in the VTA
(see Wise, 1998), although they also have rewarding actions in
other brain regions such as the nucleus accumbens (NAcc) (Olds,
1982; see Koob and Nestler, 1997).
The rewarding properties of opiates in the VTA are likely
associated with their ability to promote DA release, particularly
from cells that project to the NAcc (e.g., Leone et al., 1991).
Opiates produce this effect by reducing tonic inhibition of the
dopaminergic neurons through actions at m and d receptors on
GABAergic interneurons (Gysling and Wang, 1983; Johnson and
North, 1992). However, there is recent evidence that the excita-
tory effects of glutamate at AMPA receptors located on VTA
dopaminergic neurons are also involved in the actions of drugs of
abuse, with increased AMPA receptor function seen after
chronic drug exposure (Zhang et al., 1997). Furthermore, re-
peated intermittent drug exposure upregulates expression of the
AMPA receptor subunit GluR1 in the VTA (Fitzgerald et al.,
1996), and selective overexpression of GluR1 in the rostral VTA
by viral-mediated gene transfer can enhance the rewarding effects
of morphine (Carlezon et al., 1997). These results suggest that
drug exposure causes increased formation of Ca21-permeable
AMPA receptors and subsequent increased sensitivity of dopa-
minergic neurons to the excitatory effects of glutamate.
One advantage of viral-mediated gene transfer is that the
location of neurons that overexpress the transgene (e.g., GluR1)
can be precisely determined using immunohistochemical analy-
ses. This anatomical specificity allows a more precise analysis of
the neural substrate of opiate actions within the VTA compared
with studies in which conclusions are based on the location of a
microinjection site from which opiates diffuse. Through the use of
viral-mediated transfer of GluR1 into the VTA, we now report
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that there is a topographical organization of opiate reward-
relevant sites within the VTA itself, similar to that reported by
Bozarth (1987). Using place conditioning, we have determined
that GluR1 overexpression in rostral VTA dramatically increases
the rewarding effects of a low (threshold) dose of systemic mor-
phine, whereas GluR1 overexpression in caudal VTA makes the
same morphine treatment aversive.
MATERIALS AND METHODS
A total of 110 male Sprague Dawley rats (325–375 gm) were used; 106
were used for the place-conditioning studies, and 4 were used for dual-
labeling studies to determine the identities of neurons expressing the
viral transgenes. Place conditioning occurred in a three-compartment
apparatus, as described (Carlezon et al., 1997). On the screening day (day
0) rats were placed in the small (12 3 18 3 33 cm) central compartment
and were allowed to explore the entire apparatus for 30 min; compart-
ments differed in floor texture, wall striping, and lighting. Rats that did
not show a baseline preference ($18 min) for a compartment were
anesthetized (65 mg/kg sodium pentobarbital, i.p.) and received unilat-
eral VTA microinjections (2.0 ml over 10 min) of either herpes simplex
virus (HSV)-GluR1 (expressing GluR1; n 5 49) or HSV-LacZ (express-
ing b-galactosidase, a control protein; n 5 39) or sham surgery (n 5 18).
For the place-conditioning studies, anteroposterior (AP) coordinates
(Paxinos and Watson, 1986) ranged from 4.2 to 6.4 mm posterior to
bregma, with lateral 5 62.0 and dorsoventral 5 7.6 mm below dura; the
injection syringe was angled at 10° from the midline. For sham surgery,
the injection needle (26 gauge) was lowered 1.0 mm below dura, but no
injections were made. For dual-labeling studies, injections of HSV-
GluR1-GFP [expressing a GluR1-green fluorescent protein (GFP) fu-
sion protein; Shi et al., 1999] were aimed at the middle of the VTA (AP,
25.3 mm posterior to bregma).
Conditioning trials (two per day) were given on 2 consecutive days
(days 3 and 4). On the first conditioning trial of each day, rats received
saline (1 ml/kg, s.c.) and were confined to one of the large (24 3 18 3 33
cm) side compartments of the apparatus for 1 hr; 3 hr later, rats received
morphine (0.5 mg/kg, s.c.) and were confined to the other side compart-
ment for 1 hr. On the following day (day 5), rats were again allowed to
freely explore the entire apparatus for 30 min. Place-conditioning data
were analyzed using a one-way ANOVA, followed by post hoc compar-
isons with Dunnett’s t tests (two-tailed) using sham-treated rats as
controls.
Construction of the viral vectors has been described elsewhere (Neve
et al., 1997). For place-conditioning studies, GluR1 or LacZ cDNAs were
inserted into the HSVPrpUC amplicon, packaged with helper 5dl1.2,
purified on a sucrose gradient, pelleted, and resuspended in 10% sucrose.
For dual-labeling studies, cDNA for GluR1-GFP was inserted into the
amplicon. Average titer of the viral stocks was 2.0 3 10 7 infectious
units/ml; transgene expression was regulated by HSV IE 4/5.
After testing (or 3 d after microinjections of HSV-GluR1-GFP), rats
were overdosed with pentobarbital and perfused with 0.9% saline fol-
lowed by 4% paraformaldehyde. Brains were post fixed for 24 hr and kept
overnight in 20% glycerol before slicing. Slices (40 mm) were examined
for expression of GluR1 (using anti-GluR1, 1:100; Chemicon, Temecula,
CA) or of b-galactosidase (using 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranosidase, 0.2 mg/ml; Boehringer Mannheim, Indianapolis,
IN) according to described methods (Carlezon et al., 1997). For each
brain, the area of maximal transgene expression was determined in every
sixth slice with the assistance of an observer blinded to the behavioral
data. Some slices were stained for tyrosine hydroxylase (TH; using
anti-TH, 1:2000; Eugene Tech International) or analyzed by Nissl
staining.
Confocal microscopy was used to determine the percentage of GluR1-
overexpressing neurons that were dopaminergic in the anterior and
posterior portions of the VTA. Slices (20 mm) were incubated simulta-
neously in a rabbit-derived antibody for GFP (to identify neurons over-
expressing the GluR1-GFP fusion protein; Molecular Probes, Eugene
OR; 1:400) and a mouse-derived antibody for TH (to identify dopamine-
containing neurons: Chemicon; 1:800). Using a confocal microscope
(TCS NT; Leica, Nussloch, Germany), GFP immunoreactivity was visu-
alized with FITC-conjugated goat anti-rabbit IgG (Cappel, West Ches-
ter, PA; 1:200), and TH immunoreactivity was visualized with
rhodamine-conjugated goat anti-mouse IgG (Cappel; 1:200). Laser exci-
tation wavelengths and filters specific for visualizing FITC and rhoda-
mine were used. The total number of GFP-labeled cells throughout the
rostral–caudal extent of the VTA was determined in every sixth brain
slice, and the percentage of those cells that co-expressed TH was calcu-
lated. Between-region differences were analyzed using an F test.
RESULTS
TH immunoreactivity in the portion of the midbrain comprising
the VTA (Paxinos and Watson, 1986) was found along an ;1.8
mm rostral–caudal axis, corresponding to ;4.4–6.2 mm poste-
rior to bregma. In the rostral portions of the VTA (Fig. 1A),
TH-positive cell bodies were most apparent medially, dorsal to
the mammilary peduncle; this area of the VTA, together with
immediately adjacent regions such as the supramamillary nucleus,
is known to contain significant numbers of TH-containing neu-
rons from the A10 (mesolimbic) cell group (Dahlstrom and Fuxe,
1964; Swanson, 1982). In the caudal portions of the VTA (Fig.
1D), TH-positive cell bodies were apparent medially and later-
ally, to the point of the delineation of the substantia nigra com-
pacta. As reported previously (Carlezon et al., 1997), microinjec-
tions of HSV-LacZ or HSV-GluR1 into the VTA results in
;1000–2000 transgene-labeled cells 3 d after viral vector treat-
ment (when place conditioning and drug pairing was initiated);
however, when the rats in the present study were killed after
testing, 5 d after gene transfer, these numbers were typically
lower (see Fig. 1B,E,F), because of the transient nature of trans-
gene expression (Carlezon et al., 1997; Neve et al., 1997). There
were no apparent differences in the total number of infected
neurons between rostral versus caudal VTA injection placements.
HSV vectors caused minimal damage (Fig. 1C; Carlezon et al.,
1997) that was indistinguishable from that caused by injection of
vehicle (10% sucrose).
The effects of morphine (0.5 mg/kg, s.c.) on place conditioning
(Fig. 2) depended on the type of treatment at surgery (F(8,98) 5
3.33; p , 0.01). The effects of morphine in rats given HSV-LacZ
did not differ at any coordinate from those in rats that received
sham surgery (controls). However, the effects of morphine in rats
given HSV-GluR1 differed profoundly according to placement:
rats spent significantly more time in morphine-associated envi-
ronments than controls when viral-mediated overexpression of
GluR1 was maximal in the rostral VTA [corresponding to 4.4–5.3
mm posterior to bregma, rostral to the level of the interpedun-
cular nucleus (IPN)], whereas rats spent significantly less time in
morphine-associated environments than controls when GluR1
overexpression was maximal in the caudal VTA (corresponding
to 5.3–6.2 mm posterior to bregma, at, and caudal to, the level of
the IPN). Microinjections of HSV-GluR1 outside of the VTA
(,4.4 or .6.2 mm posterior to bregma) had no effect on mor-
phine place conditioning.
Confocal microscopy (Fig. 3) revealed that 59% of the cells
overexpressing the GluR1-GFP fusion protein in the rostral VTA
were TH-positive (i.e., dopaminergic), whereas 71% of the GluR1-
GFP-positive cells in the caudal VTA were dual-labeled. This
difference was not statistically significant (F(12,37) 5 1.16; NS).
DISCUSSION
Viral-mediated overexpression of GluR1 in the rostral VTA
dramatically enhances the rewarding effects of a threshold dose of
morphine (0.5 mg/kg, s.c.), whereas GluR1 overexpression in the
caudal VTA makes the same dose of the drug aversive. Overex-
pression of GluR1 results in increased formation of Ca21-
permeable (GluR1-homomeric) AMPA receptors (Carlezon et
al., 1997; Neve et al., 1997), which presumably causes increases in
sensitivity to the excitatory (depolarizing) effects of glutamate in
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Figure 1. Histological examination of the VTA. A, Expression of TH in the rostral VTA (;4.8 mm posterior to bregma). Large numbers of darkly
stained, TH-positive neurons are located medially at this level of the VTA (magnification, 253). B, Expression of b-galactosidase 5 d after injection of
HSV-LacZ into the left VTA. Morphine reward was enhanced by microinjections of HSV-GluR1 into this portion of the VTA but not by similar
treatment with HSV-LacZ. C, Adjacent, Nissl-stained section from the same brain as in B, showing lack of gliosis in the region of transgene expression.
D, Expression of TH in the caudal VTA (;5.8 mm posterior to bregma). Darkly stained, TH-positive neurons are distributed medially and laterally at
this level of the VTA. In addition to cell bodies, neuropil is also stained darkly at this level. E, Expression of GluR1 5 d after injection of HSV-GluR1
into the left VTA. Morphine was made aversive by microinjections of HSV-GluR1 into this region of the VTA but not by similar treatment with
HSV-LacZ. Note the endogenous GluR1 immunoreactivity in the IPN, the primary anatomical landmark used for determining rostral or caudal
placements. F, Higher magnification (1003) of the slice in (E). MP, Mammilary peduncle; SNC, substantia nigra compacta.
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the dopaminergic neuron-rich VTA. These studies using viral-
mediated gene transfer and systemic drug administration support
previous studies using intracranial drug administration that sug-
gest topographical differences in the reward-relevant properties
of drugs within the VTA (Bozarth, 1987; Ikemoto et al., 1997b).
Moreover, because the immunohistochemical analyses used in the
present studies allow precise anatomical localization of neurons
affected by gene transfer, for the first time portions of the VTA
have been identified within which opiates may have aversive
actions.
There are several possible explanations for these results. First,
it is possible that different populations of neurons mediate the
effects of GluR1 overexpression in the rostral VTA than in the
caudal VTA. Both the rostral and caudal VTA contain large
numbers of TH-positive cell bodies, although more neuropil TH
staining is evident in the caudal VTA (Fig. 1, compare A, D).
Dual-labeling immunohistochemistry studies show that the ma-
jority of cells induced virally to overexpress GluR1 were TH-
positive (i.e., dopaminergic) in both the anterior and posterior
VTA, although the percentage was slightly (12%) lower in the
anterior VTA. Because the HSV vectors used are not selective for
any particular type of neuron, the behavioral effect observed
would be expected to reflect increased sensitivity of the predom-
inant type of neuron to the excitatory effects of glutamate. Based
on independent observations, increased excitability of GABAer-
gic interneurons (the other predominant neuronal type within the
VTA) in either the rostral or caudal VTA is unlikely to cause the
pattern of behavioral effects seen in the present study. Rats
self-administer the GABAA antagonist picrotoxin directly into
the anterior VTA (Ikemoto et al., 1997b), where viral-mediated
GluR1 overexpression caused morphine place preferences.
Blockade of GABAA receptors in the anterior VTA causes
marked increases in extracellular concentrations of DA in the
NAcc (Ikemoto et al., 1997a), an effect presumably caused by
decreases in GABA-mediated inhibition of midbrain dopaminer-
gic neurons. Thus, decreases in GABA inhibition caused by
picrotoxin in the anterior VTA likely have consequences similar
to increases in the excitability of dopaminergic neurons caused by
viral-mediated overexpression of GluR1-homomeric receptors.
Conversely, rats do not self-administer picrotoxin into the poste-
rior VTA (Ikemoto et al., 1997b), where overexpression of GluR1
caused morphine place aversions. These previous studies provide
further support for the notion that there is significant heteroge-
neity of drug actions between the rostral and caudal VTA, similar
to that identified for morphine in the present studies.
A second possibility is that dopaminergic neurons in the rostral
VTA might have fundamentally different characteristics from
those in the caudal VTA. There is evidence from retrograde
labeling studies that the forebrain projection patterns of dopami-
nergic cells in the caudal VTA differ substantially from those in
the rostral VTA: caudal VTA sites appear to project predomi-
nantly to the prefrontal cortex (PFC) and NAcc shell, whereas
rostral sites appear to project predominately to the NAcc shell
and core (Brog et al., 1993). However, the relevance of this
difference in projection patterns for opiate reward is unknown;
although both the PFC and NAcc shell (but not the NAcc core)
appear to contribute to stimulant reward (see Carlezon and Wise,
1996), the precise substrates of opiate reward within the NAcc
have not been identified. Earlier studies that do not distinguish
between the NAcc core and shell suggest that GABAergic pro-
jection neurons of the NAcc differentially innervate the anterior
and posterior VTA (Walaas and Fonnum, 1980), with a more
substantial innervation of regions in which viral-mediated over-
expression of GluR1 increased morphine reward. Also, differen-
tial projections from these VTA subregions to brain regions other
than the PFC and NAcc may contribute to the behavioral effects
observed. For example, the rostral but not caudal VTA sends
direct descending projections to the laterodorsal tegmental nu-
cleus (Cornwall et al., 1990). This region, together with the
adjacent and neurochemically related pedunculopontine nucleus,
are pontine nuclei that have been implicated in opiate reward
(Olmstead et al., 1998). The consequences of differentially chang-
ing the sensitivity of these neuronal circuits to the excitatory
effects of glutamate by overexpression of GluR1 in the VTA are
not known but could be addressed in future studies by using
electrical stimulation delivered through electrodes placed in ei-
ther the rostral or caudal portions of the VTA. It is also conceiv-
able that topographically localized alterations in the function of
VTA AMPA receptors fundamentally affect the actions of mor-
phine in other, distal brain regions (e.g., the NAcc; Olds, 1982).
Finally, it is possible that the dopaminergic cells of the caudal
VTA are more sensitive to the excitatory (Gysling and Wang,
1983) effects of opiates, and that viral-mediated overexpression of
GluR1 renders affected neurons particularly susceptible to depo-
larization blockade because of consequent increases in sensitivity
to glutamate. Depolarization blockade of VTA dopaminergic
neurons would be expected to decrease DA release in the NAcc,
a condition that could be associated with diminished reward or
aversion (see Rompre´ and Wise, 1989). This possibility is not
easily addressed pharmacologically in rats given intra-VTA mi-
Figure 2. Effect of a threshold dose of morphine (0.5 mg/kg, s.c., for 2 d)
on place conditioning in rats given HSV-GluR1 or HSV-LacZ into the
VTA. Control rats received sham surgery. Place-conditioning data are
presented as mean 6 SEM change (before minus after) in time (seconds)
spent in the morphine-associated environment. Rats given HSV-GluR1
into the rostral VTA spent significantly more time in morphine-associated
environments than controls (sham), whereas those given HSV-GluR1 into
the caudal VTA spent less time in morphine-associated environments.
HSV-GluR1 had no consequence on morphine place conditioning when
placements were made anterior (out-rostral ) or posterior (out-caudal ) to
the VTA; likewise, HSV-LacZ had no effect at any coordinate. *p , 0.05;
**p , 0.01 (Dunnett’s t test) compared with sham control for each
placement; numbers in parentheses indicate the number of rats given each
treatment (e.g., HSV-GluR1 or HSV-LacZ).
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croinjections of viral vectors, however, because opiates also have
direct rewarding actions at opioid receptors in the NAcc (Olds,
1982) that may make studies in which the test dose of morphine is
altered difficult to interpret. Rather, this possibility will be ad-
dressed in future studies by examining the electrophysiological
properties of GluR1-overexpressing neurons isolated from the
rostral or caudal VTA, identified visually with the GluR1-GFP
fusion protein (Shi et al., 1999). Regardless, the present studies
demonstrate the utility of viral-mediated gene transfer for studying
the anatomical substrates of drug action and have revealed within
the VTA topographically separable motivational effects of opiates.
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Figure 3. Confocal microscopy (magnification, 4003) in a representative slice from the rostral VTA (;4.9 mm posterior to bregma). A, Cells expressing
the GluR1-GFP fusion protein are represented by green (FITC) fluorescence. B, Cells expressing TH are represented by red (rhodamine) fluorescence.
C, Overlay of A and B, revealing that four of the eight brightly labeled GluR1-GFP cells (50%) are dual-labeled, represented by yellow fluorescence.
Arrows indicate co-labeled cells.
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